Recombinant Human Cadherin-13 (CAD-13) Protein, CF Summary
Details of Functionality |
Measured by the ability of the immobilized protein to inhibit the adhesion of HUVEC human umbilical vein endothelial cells. When 5 x 104 cells/well are added to rhCadherin-13 coated plates, cell adhesion is inhibited in a dose dependent manner after 2 hours at 37 °C. The ED50 for this effect is 2-8 μg/mL. |
Source |
Mouse myeloma cell line, NS0-derived human Cadherin-13 protein Glu23-Ala692, with a C-terminal 6-His tag |
Accession # |
|
N-terminal Sequence |
Glu23 |
Protein/Peptide Type |
Recombinant Proteins |
Gene |
CDH13 |
Purity |
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
Endotoxin Note |
<0.10 EU per 1 μg of the protein by the LAL method. |
Applications/Dilutions
Dilutions |
|
Theoretical MW |
74.5 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
SDS-PAGE |
100-115 kDa, reducing conditions |
Packaging, Storage & Formulations
Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
|
Buffer |
Lyophilized from a 0.2 μm filtered solution in MES and NaCl. |
Purity |
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
Reconstitution Instructions |
Reconstitute at 200 μg/mL in PBS. |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human Cadherin-13 (CAD-13) Protein, CF
Background
Cadherin-13, also known as T-Cadherin and H‑Cadherin, is a GPI-anchored protein belonging to the Cadherin superfamily of calcium-dependent adhesion molecules. Cadherins are involved in multiple processes including embryonic development, cell migration, and maintenance of epithelial integrity (1, 2). Following removal of its C‑terminal propeptide, Cadherin-13 is expressed on the cell surface both with and without its N-terminal propeptide in species of approximately 120 kDa and 100 kDa, respectively (3). Human Cadherin-13 contains five tandem Cadherin repeats and shares 95% aa sequence identity with mouse and rat Cadherin-13 (4). It is most highly expressed in the circulatory and nervous systems, particularly on cardiac myocytes, vascular endothelial and smooth muscle cells, and neurons and astrocytes in the brain (3, 5 - 9). Cadherin-13 exerts a negative influence on neurite extension, and it is down‑regulated in neurons upon NGF stimulation (10, 11). Homotypic Cadherin-13 interactions promote intercellular adhesion which can be inhibited by its binding to LDL (12). Cadherin-13 also mediates the cardioprotective effects of Adiponectin by directly binding Adiponectin (selectively the hexameric and HMW forms) and trapping it on vascular endothelial cells and cardiomyocytes (6 ‑ 8). The role of Cadherin-13 in the vasculature is complex. When expressed on vascular endothelial cells it promotes angiogenesis, but when expressed on stromal cells it inhibits neovascularization (13, 14). Its down‑regulation on breast carcinoma cells and up‑regulation on the vasculature of various tumors limits tumor cell proliferation and angiogenesis but also enhances tumor progression (4, 8, 15).
- Pokutta, S. and W.I. Weis (2007) Annu. Rev. Cell Dev. Biol. 23:237.
- Philippova, M. et al. (2009) Cell. Signal. 21:1035.
- Stambolsky, D.V. et al. (1999) Biochim. Biophys. Acta 1416:155.
- Lee, S.W. (1996) Nat. Med. 2:776.
- Doyle, D.D. et al. (1998) J. Biol. Chem. 273:6937.
- Denzel, M.S. et al. (2010) J. Clin. Invest. 120:4342.
- Hug, C. et al. (2004) Proc. Natl. Acad. Sci. 101:10308.
- Hebbard, L.W. et al. (2008) Cancer Res. 68:1407.
- Takeuchi, T. et al. (2000) J. Neurochem. 74:1489.
- Fredette, B.J. et al. (1996) Development 122:3163.
- Bai, S. et al. (2007) J. Biol. Chem. 282:27171.
- Resink, T.J. et al. (1999) FEBS Lett. 463:29.
- Philippova, M. et al. (2006) Arterioscler. Thromb. Vasc. Biol. 26:2222.
- Rubina, K. et al. (2007) Angiogenesis 10:183.
- Wyder, L. et al. (2000) Cancer Res. 60:4682.
Customers Who Viewed This Item Also Viewed...
Species: Hu, Rb, Rt
Applications: Flow, IHC, IHC-P, KO, WB
Species: Hu
Applications: IHC, IHC-P, KD, WB
Species: Hu
Applications: AgAct, Simple Western, WB
Species: Hu, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu, Rt
Applications: ELISA
Species: Hu
Applications: BA
Species: Mu, Rt
Applications: ELISA, ICC/IF, IHC, IHC-Fr, IHC-P, WB
Species: Mu
Applications: Simple Western, WB
Species: Mu, Rt
Applications: WB
Species: Ca, Hu, Pm, Po, Pm, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, WB
Species: Rt
Applications: ICC, IHC, IP, KO, WB
Species: Hu, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu
Applications: CyTOF-ready, Dual ISH-IHC, Flow, ICC, IHC, Simple Western, WB
Species: Hu, Mu, Rt
Applications: ELISA, ICC/IF, IHC, IHC-P, IP, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P, IP, WB
Species: Hu
Applications: ICC, Simple Western, WB
Species: Hu
Applications: ELISA
Species: Ca(-), Hu, Rt(-)
Applications: Flow-IC, Flow, ICC/IF, IF, IHC, IHC-P, MI, WB
Species: Hu, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, WB
Publications for Cadherin-13 (3264-CA) (0)
There are no publications for Cadherin-13 (3264-CA).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for Cadherin-13 (3264-CA) (0)
There are no reviews for Cadherin-13 (3264-CA).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
FAQs for Cadherin-13 (3264-CA) (0)
Additional Cadherin-13 Products
Blogs on Cadherin-13